-
Sector Analysis
NewCell and Gene Therapies in Ophthalmology – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in Ophthalmology Market Report Overview The Cell and Gene Therapies (CGT) in ophthalmology market was $46 million in 2023. The market will experience moderate growth during the forecast period with gene therapies targeting Leber congenital amaurosis (LCA) and retinitis likely to be the primary drivers of the CGT market in the ophthalmology space. The CGT in ophthalmology market research report will aid clients in gaining insight into the competitive landscape of leading CGT agents in ophthalmology...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vyznova in Corneal Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vyznova in Corneal Edema report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vyznova in Corneal Edema Drug Details: Vyznova a human corneal endothelial cell...
-
Product Insights
Corneal Edema – Drugs In Development, 2023
Global Markets Direct’s, ‘Corneal Edema - Drugs In Development, 2023’, provides an overview of the Corneal Edema pipeline landscape. The report provides comprehensive information on the therapeutics under development for Corneal Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Corneal Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Corneal Dystrophy - Drugs In Development, 2023’, provides an overview of the Corneal Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Corneal Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AE-101
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AE-101 Drug Details AE-101 is under development for the treatment of corneal endothelial dysfunction...